Lung cancer

Open Access
Non-Invasive Direct Visualization of Luciferase-Luciferin Emitted Light Producing True Images from an Orthotopic Lung Cancer Xenograft Model in Nude Mice Using an Ultra-sensitive Low-light Camera and Optics
KOHEI MIZUTA, SEAN GALLAGHER, APRIL WANG, NEIL CHANG, SEI MORINAGA, MOTOKAZU SATO, BYUNG MO KANG and ROBERT M. HOFFMAN

In Vivo September 2024, 38 (5) 2122-2125; DOI: https://doi.org/10.21873/invivo.13674
Open Access
Progression to Lymph Node Metastasis After Spontaneous Regression of Pulmonary Adenocarcinoma Following Biopsy
KYOICHI KAIRA, HISAO IMAI, ATSUTO MOURI, OU YAMAGUCHI and HIROSHI KAGAMU

In Vivo May 2024, 38 (3) 1498-1502; DOI: https://doi.org/10.21873/invivo.13597
Open Access
Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report
TAKAHIRO HIRAI, MINEHIKO INOMATA, SHUHEI MINATOYAMA, MOE HASHIZUME, NAOKI TAKATA, KANA HAYASHI, ZENTA SETO, KOTARO TOKUI, CHIHIRO TAKA, SEISUKE OKAZAWA, KENTA KAMBARA, SHINGO IMANISHI, TOSHIRO MIWA, RYUJI HAYASHI, SHINICHI TANAKA, AKIRA NOGUCHI and TSUTOMU SATO

In Vivo May 2024, 38 (3) 1509-1511; DOI: https://doi.org/10.21873/invivo.13599
Open Access
Polyphyllin II (PPII) Enhances the Sensitivity of Multidrug-resistant A549/DDP Cells to Cisplatin by Modulating Mitochondrial Energy Metabolism
LIAN PENG, RENYI YANG, ZHIBING WANG, HUIYING JIAN, XIAONING TAN, JIAN LI, ZUOMEI HE, RUI HUANG, PUHUA ZENG and WENHUI GAO

In Vivo January 2024, 38 (1) 213-225; DOI: https://doi.org/10.21873/invivo.13428
Open Access
Association Between Clinicopathological Parameters and S100A8/A9 Expression According to Smoking History in Patients With Non-small Cell Lung Cancer
SUNG BAE CHO, IN KYOUNG KIM, CHANG DONG YEO and SANG HAAK LEE

In Vivo January 2024, 38 (1) 474-481; DOI: https://doi.org/10.21873/invivo.13462
Open Access
Renieramycin T Derivative DH_22 Induces p53-dependent Apoptosis in Lung Cancer Cells
INDIANA GITA ANGGRAENI, ZIN ZIN EI, DAIKI HOTTA, MASASHI YOKOYA and PITHI CHANVORACHOTE

In Vivo September 2023, 37 (5) 1960-1966; DOI: https://doi.org/10.21873/invivo.13292
Open Access
Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer
JIRI BLAZEK, PETR HOSEK, KAROLINA HRABCOVA, MONIKA BRATOVA, JURAJ KULTAN, MICHAL HRNCIARIK, MARKETA CERNOVSKA, PETRA ZEMANOVA, JANA KREJCI, LEONA KOUBKOVA, MAREK STASTNY and MARTIN SVATON

In Vivo September 2023, 37 (5) 2229-2236; DOI: https://doi.org/10.21873/invivo.13324
Open Access
Serum Albumin Affects the Time-to-treatment Failure of Alectinib: A Multicenter Retrospective Study
KENGO UMEHARA, KAORI YAMA, KEISUKE GOTO, TAKANOBU HOSHI, TOMOAKI HATAKEYAMA, MARIKO ISAJI, SHINYA TAKADA, KAYO YAMAGISHI, KOZO MINO and HIDEKI SATO

In Vivo September 2023, 37 (5) 2260-2267; DOI: https://doi.org/10.21873/invivo.13328
Open Access
The Association of DNA Ligase 1 Rs20579 Polymorphism With Lung Cancer Risk Among Taiwanese
SHANG-MIAO CHANG, YA-CHEN YANG, GUAN-LIANG CHEN, LI-HSIOU CHEN, TE-CHUN SHEN, YEN-FENG LIU, YUN-CHI WANG, CHIA-WEN TSAI, TE-CHUN HSIA, DA-TIAN BAU and WEN-SHIN CHANG

In Vivo July 2023, 37 (4) 1504-1510; DOI: https://doi.org/10.21873/invivo.13235
Open Access
Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience
SANG-GON PARK, HEE JEONG LEE, SEUL BI LEE and RAN HONG

In Vivo January 2023, 37 (1) 233-241; DOI: https://doi.org/10.21873/invivo.13072

Main menu

User menu

Search

Lung cancer

Pages